TGFB1 and pemphigus foliaceus: have found through in vitro and animal experiments that MSCs can inhibit TGF-β1 production by secreting HGF through the paracrine pathway and improve TGF-β1-stimulated EMT in HPMCs through the TGF-β1/smad2 signaling pathway, thereby alleviating PF and reducing peritoneal functional impairment.